Literature DB >> 14688053

Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype.

Maurizio Zazzi1, Laura Romano, Giulietta Venturi, Robert W Shafer, Caroline Reid, Federico Dal Bello, Cristina Parolin, Giorgio Palù, Pier E Valensin.   

Abstract

OBJECTIVES: To compare three methods for using HIV-1 genotype to predict antiretroviral drug susceptibility.
METHODS: We applied three genotypic interpretation algorithms to 478 reverse transcriptase (RT) and 410 protease sequences for which phenotypic data were available. Sequences were obtained from clinical practice and from published sequences in the Stanford HIV-1 RT and Protease Sequence Database. The genotypic interpretation algorithms included: Stanford HIVdb program (HIVdb), the Visible Genetics/Bayer Diagnostics Guidelines 6.0 (VGI) and a genotypic interpretation program (AntiRetroScan, ARS) developed at the University of Siena, Italy. Genotypic interpretations were normalized to a three-level output: susceptible, intermediate and resistant. Discordances were defined as differences between genotype and phenotype for the same virus isolate. Discordances for which an isolate was considered susceptible by one test but resistant by another test were considered major discordances.
RESULTS: The frequency of major discordances between genotype and phenotype was 10.6, 13.7 and 15.7% for ARS, VGI and HIVdb, respectively (P < 0.0001 for ARS versus HIVdb and for ARS versus VGI; P = 0.002 for VGI versus HIVdb). The correlation between genotype and phenotype was highest for non-nucleoside RT inhibitors and lowest for nucleoside RT inhibitors. Half of the major discordances involved stavudine, didanosine and zalcitabine. The concordance among the three genotypic algorithms was high, with weighted Kappa values ranging between 0.76 and 0.84 for the pairwise comparisons between each of the algorithms.
CONCLUSIONS: Genotype interpretation algorithms correctly predict phenotype in 85-90% of cases, but the rate of concordance is not uniformly distributed among different drugs. These data provide insight into the potential additional benefit derived from phenotyping.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688053     DOI: 10.1093/jac/dkh021

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Application of Radial Basis Function Network Tool for Correlation of CD4+ Count with Plasma Viral Load in HIV-Seropositive Individuals.

Authors:  Arnaw Kishore; Sumana M Neelambike
Journal:  J Clin Diagn Res       Date:  2016-04-01

2.  A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.

Authors:  Daphne Monie; Rachel P Simmons; Richard E Nettles; Tara L Kieffer; Yan Zhou; Haili Zhang; Sharon Karmon; Roxann Ingersoll; Karen Chadwick; Hao Zhang; Joseph B Margolick; Thomas C Quinn; Stuart C Ray; Megan Wind-Rotolo; Michael Miller; Deborah Persaud; Robert F Siliciano
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

4.  Web resources for HIV type 1 genotypic-resistance test interpretation.

Authors:  Tommy F Liu; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2006-04-28       Impact factor: 9.079

5.  Predicting drug resistance of the HIV-1 protease using molecular interaction energy components.

Authors:  Tingjun Hou; Wei Zhang; Jian Wang; Wei Wang
Journal:  Proteins       Date:  2009-03

6.  Dynamical basis for drug resistance of HIV-1 protease.

Authors:  Yi Mao
Journal:  BMC Struct Biol       Date:  2011-07-08

7.  PharmGED: Pharmacogenetic Effect Database.

Authors:  C J Zheng; L Y Han; B Xie; C Y Liew; S Ong; J Cui; H L Zhang; Z Q Tang; S H Gan; L Jiang; Y Z Chen
Journal:  Nucleic Acids Res       Date:  2006-12-06       Impact factor: 16.971

8.  Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

Authors:  Andrea De Luca; Philippe Flandre; David Dunn; Maurizio Zazzi; Annemarie Wensing; Maria Mercedes Santoro; Huldrych F Günthard; Linda Wittkop; Theodoros Kordossis; Federico Garcia; Antonella Castagna; Alessandro Cozzi-Lepri; Duncan Churchill; Stéphane De Wit; Norbert H Brockmeyer; Arkaitz Imaz; Cristina Mussini; Niels Obel; Carlo Federico Perno; Bernardino Roca; Peter Reiss; Eugen Schülter; Carlo Torti; Ard van Sighem; Robert Zangerle; Diane Descamps
Journal:  J Antimicrob Chemother       Date:  2016-01-28       Impact factor: 5.790

9.  HIV Drug-Resistant Patient Information Management, Analysis, and Interpretation.

Authors:  Yashik Singh; Maurice Mars
Journal:  JMIR Res Protoc       Date:  2012-06-07

10.  Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis.

Authors:  Awachana Jiamsakul; Rami Kantor; Patrick C K Li; Sunee Sirivichayakul; Thira Sirisanthana; Pacharee Kantipong; Christopher K C Lee; Adeeba Kamarulzaman; Winai Ratanasuwan; Rossana Ditangco; Thida Singtoroj; Somnuek Sungkanuparph
Journal:  BMC Res Notes       Date:  2012-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.